The phospholipase A2 receptor 1 (PLA2R1) is the major autoantigen in patients suffering
from membranous nephropathy. To date, the lack of endogenous glomerular expression of …

Rituximab induces nephrotic syndrome (NS) remission in two-thirds of patients with primary
membranous nephropathy (MN), even after other treatments have failed. To assess the …

Autoantibodies to M-type phospholipase A2 receptor (PLA2R) are specific markers of
idiopathic membranous nephropathy (IMN). They can differentiate IMN from other …

Renal biopsy is the gold standard for diagnosis of membranous nephropathy. Circulating
PLA 2 R1 antibody found in 75% of patients with membranous nephropathy is very specific …

As recently as 2002, most cases of primary membranous nephropathy (MN), a relatively
common cause of nephrotic syndrome in adults, were considered idiopathic. We now …

Primary membranous nephropathy is a leading cause of adult nephrotic syndrome. The field
took a major step forward with the identification of phospholipase A2 receptor (PLA2R) as a …

Antibody-mediated autoimmune pathologies like membranous nephropathy are difficult to
model, particularly in the absence of local target antigen expression in model organisms …

Background Circulating serum autoantibodies against the M-type phospholipase A2
receptor (PLA2R-AB) are a key biomarker in the diagnosis and monitoring of primary …

Results Remissions occurred in 18 (64%) versus eight (30%) from the NICE and GEMRITUX
cohort (P= 0.02) at month 6, respectively, and in 24 (86%) versus 18 (67%) participants (P …

Membranous nephropathy is a major cause of nephrotic syndrome of non-diabetic origin in
adults. It is the second or third leading cause of end-stage renal disease in patients with …